Evogene Ltd
EVGN
Closed
$0.59
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. The company is headquartered in Rehovot, Central(Hamerkaz) and currently employs 142 full-time employees. The company went IPO on 2007-06-11. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Key stats
Open
$0.58
Volume
1.04M
Market cap
$8.89M
Prev. close
$0.56
Impl / hst vl
-
Open interest
$0.00
$0.49
Day’s Range
$0.74
$0.37
52W Range
$1.24
Valuation
5
Valuation score
Strongly Overvalued
P/E
-
P/S
-
P/B
-
Current ratio
-
Debt / Equity
-
ROE
-
Gross margin
-
Income growth
-69.88%
FCF growth
-32.92
Analysts estimates
Consensus rating
Buy
The average rating from top 4 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$2.19
The top 3 analysts forecasts that 12-month price may increase by 271.69%, with a low of $2.17 and a high of $2.26
$2.17
Low
$2.19
Avg
$2.26
High
Current price
Earnings
Q2 ‘26 revenue
$347.00K
Q2 ‘26 net income
-$1.77M
Revenue
Net income
Previous EPS
-$0.60
Estimate EPS
-$0.28
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply